Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK7 | Q13164 | 9/20 | 0.48 |
| ▸ | MAPK14 | Q16539 | 4/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 3/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.47 |
| ▸ | PKM | P14618 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | YTHDC1 | Q96MU7 | 1/20 | 0.41 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL299630 | 0.83 | POLB (0.50) | MAPK7MAPK14POLBRAB9ASMN1; SMN2 | |
| SCHEMBL300049 | 0.82 | POLB (0.68) | MAPK7MAPK14POLBRAB9ASMN1; SMN2 | |
| SCHEMBL298212 | 0.81 | POLB (0.51) | MAPK7MAPK14POLBRAB9ASMN1; SMN2 | |
| SCHEMBL29191020 | 0.74 | RAB9A (0.57) | POLBRAB9ASMN1; SMN2NPC1HSP90AA1 | |
| SCHEMBL30874534 | 0.74 | RAB9A (0.57) | POLBRAB9ASMN1; SMN2NPC1HSP90AA1 | |
| SCHEMBL695984 | 0.74 | HCAR2 (0.46) | POLBGAAHCAR2KMT2A | |
| SCHEMBL29190948 | 0.73 | SMN1; SMN2 (0.65) | POLBRAB9ASMN1; SMN2NPC1HSP90AA1 | |
| SCHEMBL17607058 | 0.73 | MAPK14 (0.67) | MAPK7MAPK14POLBRAB9ASMN1; SMN2 | |
| SCHEMBL17607055 | 0.73 | MAPK7 (0.60) | MAPK7RAB9ASMN1; SMN2NPC1HSP90AA1 | |
| SCHEMBL17607070 | 0.73 | MAPK7 (0.63) | MAPK7MAPK14POLBPKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2300485-B1 | PYRROLO-[2, 3-C]-PYRIDINE DERIVATIVES AS P38 KINASE INHIBITING AGENTS | MERCK SHARP & DOHME (US) | 2012-01-18 | — | — | EP | disclosed |
| US-8017605-B2 | P38 kinase inhibiting agents | MERCK SHARP & DOHME CORP. (US) | 2011-09-13 | — | — | US | disclosed |
| US-20110105430-A1 | PYRROLO [2,3-C] PYRIDINE DERIVATIVES AS P38 KINEASE INHIBITING AGENTS | SAHOO SOUMYA P | 2011-05-05 | — | — | US | disclosed |
| EP-2300485-A1 | PYRROLO Ý2, 3-C¨PYRIDINE DERIVATIVES AS P38 KINASE INHIBITING AGENTS | Merck Sharp & Dohme Corp. (US) | 2011-03-30 | — | — | EP | disclosed |
| US-20090325953-A1 | P38 KINASE INHIBITING AGENTS | MERCK SHARP & DOHME LLC | 2009-12-31 | — | — | US | disclosed |
| WO-2009152072-A1 | PYRROLO [2, 3-C] PYRIDINE DERIVATIVES AS P38 KINASE INHIBITING AGENTS | MERCK & CO., INC. (US) | 2009-12-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090325953-A1 | P38 KINASE INHIBITING AGENTS | MAPK1, MAPK8, MAPKAPK2 | MAPK7 4/4885MAPK14 13/4885POLB 1822/4885 |
| US-20110105430-A1 | PYRROLO [2,3-C] PYRIDINE DERIVATIVES AS P38 KINEASE INHIBITING AGENTS | MAPK1, MAP3K8, MAPK8 | MAPK7 37/4885MAPK14 33/4885POLB 888/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.